Today: 8 June 2026
Browse Category

NASDAQ:AMC 15 November 2025 - 29 May 2026

AMC Stock Rises as Summer Box Office Set to Test Theater Chain

AMC Stock Rises as Summer Box Office Set to Test Theater Chain

AMC Entertainment shares jumped 9.5% to $1.73 Friday, their biggest gain of the week, with trading volume nearly doubling from the previous session. The company drew over 5 million moviegoers worldwide during Memorial Day weekend, helped by Disney’s The Mandalorian and Grogu, which led the U.S. box office with $102 million. AMC reported a first-quarter net loss of $117.1 million and $3.96 billion in debt.
29 May 2026
····
2026 Golden Globe Nominations: ‘One Battle After Another’ Leads as Netflix–Warner Battle Jolts Hollywood Movie Stocks

2026 Golden Globe Nominations: ‘One Battle After Another’ Leads as Netflix–Warner Battle Jolts Hollywood Movie Stocks

Paul Thomas Anderson’s “One Battle After Another” led the 83rd Golden Globe nominations with nine nods, announced Monday by the Hollywood Foreign Press Association. “Sentimental Value” and “Sinners” followed closely. The ceremony airs January 11 on CBS, hosted by Nikki Glaser. The nominations land as Netflix, Warner Bros. Discovery, and Paramount battle takeover bids, impacting entertainment stocks.
9 December 2025
······
AMC Stock Today (Nov 5, 2025): Q3 Revenue Beats Estimates, Loss Widens; CEO Sees Best Q4 in Six Years

AMC Stock Today (Nov. 15, 2025): Q3 Results, Fresh 52‑Week Low, Debt Moves, and 2026 Outlook — Analysis & Forecast

AMC reported Q3 2025 revenue of $1.30 billion, beating estimates, but posted a $298.2 million net loss due to non-cash refinancing charges. Shares hit a 52-week low in November after Citi cut its price target to $2.30. Corporate borrowings stood at $3.99 billion with $366 million in cash at quarter-end. Senior leadership promotions were announced November 3.
15 November 2025
·

Stock Market Today

  • Stock Market Update: Dow Expected to Weaken, Nasdaq to Gain After Sharp Dip; Oil Prices Surge Amid Middle East Conflict
    June 8, 2026, 9:06 AM EDT. The Dow Jones Industrial Average is set to weaken while the Nasdaq Composite is poised for gains after the S&P 500 experienced its worst day since October. This downturn follows renewed violence in the Middle East, with Iran striking Israel, escalating geopolitical tensions. Oil prices jumped significantly, reflecting concerns over supply disruptions linked to the conflict. Investors remain cautious as markets digest the impact of escalating regional instability on global economic outlooks.

Latest articles

Plug Power Stock Faces a Make-or-Break Week After Friday’s 10% Drop

Plug Power Stock Faces a Make-or-Break Week After Friday’s 10% Drop

8 June 2026
Plug Power rose 2.95% to $3.31 in Monday pre-market trading after a $39.2 million federal tax credit sale tied to its St. Gabriel hydrogen facility, as investors await CEO Jose Luis Crespo’s June 11 update on liquidity and asset sales amid ongoing losses and a recent 10.69% stock drop.
ABAT Shares Jump on DOE’s $115M Lithium Grant Return

ABAT Shares Jump on DOE’s $115M Lithium Grant Return

8 June 2026
American Battery Technology Co shares soared 29.58% to $4.03 premarket after the U.S. Department of Energy fully reinstated a $115 million grant for its Nevada lithium refinery, restoring federal funding for the Tonopah Flats Lithium Project with no change to awarded funds or milestones, though risks remain from permitting, financing, and volatile lithium prices.
NANO Nuclear Stock Bounces, Investors Eye What’s Next

NANO Nuclear Stock Bounces, Investors Eye What’s Next

8 June 2026
NANO Nuclear Energy jumped 7.8% to $25.40 in premarket trading after a 9.9% Friday drop, as traders weighed fresh insider sales filings and recent regulatory progress on its KRONOS microreactor project; the company held $568.7 million in cash as of March 31, but faces sector-wide volatility and execution risks.
Nurix Shares Jump Premarket on Roche $2.3 Billion Cancer Drug Deal

Nurix Shares Jump Premarket on Roche $2.3 Billion Cancer Drug Deal

8 June 2026
Nurix soared 20.4% to $17.62 premarket after Roche agreed to pay $700 million up front in a bexobrutideg collaboration worth up to $2.3 billion, a major cash boost and external validation for Nurix’s lead blood cancer drug ahead of a planned Phase 3 trial, with Roche’s clinical and commercial backing now in play.
Go toTop